Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy

References

• Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005; 54: 242–9
   PubMed Web of Science ®Google Scholar
• Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut 2001; 48: 132–5
   PubMed Web of Science ®Google Scholar
• Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004; 3: 394–400
   PubMed Web of Science ®Google Scholar
• Macfarlane GT, Furrie E, Macfarlane S. Bacterial milieu and mucosal bacteria in ulcerative colitis. Novartis Found Symp 2004; 263: 57–70
   PubMedGoogle Scholar
• Cummings JH, Kong SC. Probiotics, prebiotics and antibiotics in inflammatory bowel disease. Novartis Found Symp 2004; 263: 99–114
   PubMedGoogle Scholar
• Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003; 52: 79–83
   PubMed Web of Science ®Google Scholar
• Kanauchi O, Matsumoto Y, Matsumura M, Fukuoka M, Bamba T. The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease. Curr Pharm Des 2005; 11: 1047–53
   PubMed Web of Science ®Google Scholar
• Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894–8
   PubMed Web of Science ®Google Scholar
• Nagashima K, Hisada, T, Sato M, Mochizuki J. Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces. Appl Environ Microbiol 2003;69:1251–62.
   PubMed Web of Science ®Google Scholar
• Kibe R, Sakamoto M, Yokota H, Ishikawa H, Aiba Y, Koga Y, et al. Movement and fixation of intestinal microbiota after administration of human feces to germfree mice. Appl Environ Microbiol 2005; 71: 3171–8
   PubMed Web of Science ®Google Scholar
• Kanauchi O, Mitsuyama K, Araki Y, Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Des 2003; 9: 333–46
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Lammers KM, Rizzello F, Campieri M. VSL#3: an analysis of basic and clinical contribution in probiotic therapeutics. Gastroenterol Clin North Am 2005; 34: 499–513
   PubMed Web of Science ®Google Scholar
• Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539–46
   PubMed Web of Science ®Google Scholar
• Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108–14
   PubMed Web of Science ®Google Scholar
• Cui HH, Chen CL, Wang JD, Yang YJ, Cun Y, Wu JB, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004; 15: 1521–5
   Google Scholar
• Sasaki M, Araki Y, Tsujikawa T, Andoh A, Fujiyama Y. Intestinal cell proliferation and microflora. J Intest Microbiol 2005; 19: 1–8
   Google Scholar
• Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617–23
   PubMed Web of Science ®Google Scholar
• Kanauchi O, Suga T, Tochihara M, Hibi T, Naganuma M, Homma T, et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol 2002; 37: 67–72
   PubMed Web of Science ®Google Scholar
• Bamba T, Kanauchi O, Andoh A, Fujiyama Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol 2002; 17: 818–24
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Saiki T, Kanauchi O, Iwanaga T, Tomiyasu N, Nishiyama T, et al. Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study. Aliment Pharmacol Ther 1998; 12: 1225–30
   PubMed Web of Science ®Google Scholar
• Suzuki A, Mitsuyama K, Koga H, Tomiyasu N, Masuda J, Takaki K, et al. Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study. Nutrition 2006; 22: 76–81
   PubMed Web of Science ®Google Scholar
• Liu WT, Marsh TL, Cheng H, Forney LJ. Characterization of microbial diversity by determining terminal restriction fragment length polymorphisms of genes encoding 16S rRNA. Appl Environ Microbiol 1997; 63: 4516–22
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Hayashi H, Benno Y. Terminal restriction fragment length polymorphism analysis for human fecal microbiota and its application for analysis of complex bifidobacterial communities. Microbiol Immunol 2003; 47: 133–42
   PubMed Web of Science ®Google Scholar